CKD

SGLT2 inhibitor — eligibility & safety

Indications across DKD, non-DKD, HFpEF/HFrEF, and contraindications.

drug safetySGLT2i

Required inputs

  • eGFR (mL/min/1.73 m²)
  • UACR (mg/g)
  • Type 2 diabetes
  • Heart failure
  • Type 1 diabetes
  • Pregnancy/lactation
  • Recurrent DKA history

Equation or source

KDIGO 2024 CKD; ESC 2023 HF update; dapa/empa/cana labels.

Provenance and release status

Equation / algorithm
Indications across DKD, non-DKD, HFpEF/HFrEF, and contraindications.
Formula version
sglt2i-2024-v1
Tool version
2.4.0
Clinical risk class
C. HIGH-RISK CLINICAL CALCULATOR
Release status
Temporarily unavailable
Source status
Direct primary source identifier not yet resolved
Clinical review status
Clinical verification incomplete; active calculation unavailable
Clinical review date
Clinical review date not yet documented

DOI / PMID / direct guideline identifier not yet documented.

Assumptions

  • Entered values and units are accurate and apply to the population described by the cited source.
  • The published equation or rule is being used without a patient-specific clinical adjustment.

Important limitations

  • The result is a calculated estimate, not a prescription, treatment order, or diagnosis.
  • Local protocols, the full clinical context, and the primary source must be checked before use.
View verification status